Department of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China.
Bioorg Med Chem. 2013 Nov 15;21(22):6956-64. doi: 10.1016/j.bmc.2013.09.027. Epub 2013 Sep 18.
2-Aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-one has been proposed as a novel scaffold of EGFR inhibitor based on scaffold hoping. In the present study, a series of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-one derivatives were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against two human cancer cell lines, including A431 and A549. The SAR of the title compounds was preliminarily discussed. The compounds with ideal inhibition were evaluated through ELISA-based EGFR-TK assay. Compound 6c showed the best activity against A431 and EGFR tyrosine kinase. These findings suggest that title compounds are EGFR inhibitors with novel structures.
2-芳基-8-羟基(或甲氧基)-异喹啉-1(2H)-酮被提议作为一种基于支架跳跃的新型 EGFR 抑制剂支架。在本研究中,合成了一系列 2-芳基-8-羟基(或甲氧基)-异喹啉-1(2H)-酮衍生物。通过 MTT 法测定了它们对两种人癌细胞系 A431 和 A549 的体外增殖活性。初步探讨了标题化合物的 SAR。通过基于 ELISA 的 EGFR-TK 测定对具有理想抑制作用的化合物进行了评估。化合物 6c 对 A431 和 EGFR 酪氨酸激酶表现出最好的活性。这些发现表明,标题化合物是具有新型结构的 EGFR 抑制剂。